论文部分内容阅读
探讨西洛他唑对糖尿病视网膜病变病理生理中的影响及可能的作用机制。用链脲佐菌素(STZ)腹腔注射建立糖尿病模型,用免疫组织化学法、实时荧光定量PCR法观察西洛他唑治疗组、糖尿病对照组和正常对照组视网膜中血小板反应素(TSP-1)的变化。每隔1周测量血糖一次,4周后糖尿病治疗组、糖尿病组与正常组大鼠的体重、血糖有显著性差异(P<0.01);糖尿病治疗组、糖尿病对照组和正常对照组间TSP-1表达有显著性差异(P<0.01)。在早期糖尿病大鼠的视网膜神经节细胞层、内核层中均有明显的TSP-1表达,糖尿病西洛他唑治疗组视网膜中TSP-1的表达要低于糖尿病对照组。实验显示西洛他唑可能通过阻止TSP-1的过度表达,在一定程度上延缓其糖尿病视网膜病变的发生。
To investigate the effect of cilostazol on the pathophysiology of diabetic retinopathy and its possible mechanism. The diabetic model was established by intraperitoneal injection of streptozotocin (STZ). The expression of thrombospondin (TSP-1) in retina of cilostazol group, diabetic control group and normal control group was detected by immunohistochemistry and real-time fluorescence quantitative PCR )The change. The blood sugar was measured once every other week, and the body weight and blood glucose of the diabetes mellitus group, the diabetic group and the normal group were significantly different after 4 weeks (P <0.01). The levels of TSP- 1 expression was significantly different (P <0.01). The expression of TSP-1 in retinal ganglion cell layer and inner nuclear layer of early diabetic rats was significantly higher than that of diabetic control group. The expression of TSP-1 in retina of diabetic cilostazol group was lower than that of diabetic control group. Experiments show that cilostazol may prevent the occurrence of diabetic retinopathy to a certain extent by blocking the overexpression of TSP-1.